Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Total HBV / HDV Franchise by Quarter
Total HBV / HDV Franchise (legacy sub-franchise breakout) — Worldwide YoY growth (%) (%)
Gilead Sciences Total HBV / HDV Franchise: -4.0% in Q4 2022, down 13.0 pts from a year earlier. That is the lowest of the 8 quarters on record here. No newer figure appears in the documents we track.
Where the Q4 2022 figure comes from
“|| HBV/HDV | 255 | 265 | (4)% | 988 | 969 | 2%”
Source: Form 8-K (exhibit991earningspressrel.htm, filed 2023-02-02) ↗
Reported in Form 8-K Total Revenue Summary.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total HBV / HDV Franchise (legacy sub-franchise breakout) — Worldwide YoY growth (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q4 2022 | Dec 31, 2022 | -4.0% | -13.0 pts | Form 8-K (exhibit991earningspressrel.htm, filed 2023-02-02) ↗ |
| Q3 2022 | Sep 30, 2022 | 7.0% | -10.0 pts | Form 8-K (exhibit991earningspressrel.htm, filed 2022-10-27) ↗ |
| Q2 2022 | Jun 30, 2022 | -1.0% | -9.0 pts | Form 8-K (exhibit991earningspressrel.htm, filed 2022-08-02) ↗ |
| Q1 2022 | Mar 31, 2022 | 7.0% | -11.0 pts | Form 8-K (exhibit991earningspressrel.htm, filed 2022-04-28) ↗ |
| Q4 2021 | Dec 31, 2021 | 9.0% | – | Form 8-K (exhibit991earningspressrel.htm, filed 2022-02-01) ↗ |
| Q3 2021 | Sep 30, 2021 | 17.0% | – | Form 8-K (exhibit991earningspressrel.htm, filed 2021-10-28) ↗ |
| Q2 2021 | Jun 30, 2021 | 8.0% | – | Form 8-K (exhibit991earningspressrel.htm, filed 2021-07-29) ↗ |
| Q1 2021 | Mar 31, 2021 | 18.0% | – | Form 8-K (exhibit991earningspressrel.htm, filed 2021-04-29) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Total HBV / HDV Franchise (%), quarterly Q1 2021–Q4 2022 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver-hbv-hdv-total-yoy
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.